23 June 2020 - Renibus Therapeutics announced today that it has been granted fast track designation by the FDA for RBT-9 treatment in COVID-19.
Preclinical studies have shown that RBT-9 protects various organs, including the lung, heart, kidney, and liver. Importantly, RBT-9 has demonstrated antiviral activity in several enveloped viruses and inhibits a key mediator of viral replication in coronaviruses, including SARS-CoV-2 – the virus that causes COVID-19.